NYSE:MAIN

Main Street Capital stock drops — what to watch before MAIN reports earnings

Main Street Capital Corp shares fell 2.4% to $59.44 Friday, underperforming as BDC peers also declined after softer U.S. inflation data. Company filings showed executive Jason Beauvais acquired 100 shares via dividend reinvestment. Main Street’s next earnings report is set for Feb. 26 after market close. U.S. markets will be shut Monday for Washington’s Birthday.

15 February 2026

Earnings Reports·NASDAQ:ARCC·NYSE:BIZD·NYSE:FSK·NYSE:MAIN·NYSE:OWL·Stock Market

ARCC stock today: Ares Capital ends 2025 near $20 as rates and dividends drive the next move

Ares Capital shares closed down 0.2% at $20.23 in the last U.S. session of 2025. Investors are watching for February earnings to gauge dividend coverage as Fed rate policy remains uncertain. Wall Street ended the year lower, with the S&P 500 off 0.74%. ARCC trades near the lower half of its 52-week range.

2 January 2026

Dividends·NASDAQ:ARCC·NASDAQ:GBDC·NYSE:BSL·NYSE:MAIN·Stock Market

McKesson Q3 2026 Earnings Shine on Specialty and Oncology Growth
March 20, 2026, 9:37 AM EDT. McKesson (MCK) reported a strong third quarter for fiscal 2026, posting 11% revenue growth and 13% rise in operating profit driven by specialty distribution, oncology services, and biopharma solutions. The company, with a $112.7 billion market cap, surpassed earnings estimates in four consecutive quarters, reflecting disciplined capital management and operational efficiency. Specialty pharmaceuticals, especially GLP-1 therapies, surged 26% year-over-year, fueling demand for high-margin, complex drug distribution. McKesson's oncology segment saw 57% profit growth, benefiting from acquisitions and organic expansion. While shares gained 29% over six months, outperforming the industry and S&P 500, margin pressures in the core pharmaceutical distribution segment could moderate gains. Investors should weigh McKesson's growth prospects against these structural challenges for long-term portfolio inclusion.